3 Biotech Stocks Poised For Growth Unrelated To COVID-19

When it comes to the race for COVID-19 vaccines that captured the attention of biotech investors last year, the author of today’s article notes that “That race is largely over, at least in the United States…And while it’s fair to say that a company like Moderna will continue to generate significant revenue from its mRNA vaccine throughout 2022, investors should be looking to shift money into other stocks in this sector.” With that, he proceeds to highlight three biotech stocks focused on areas unrelated to COVID-19 that appear poised for growth. For these three stocks, CLICK HERE.